CMC expert specialized in formulation development from discovery to clinical stage, Elizabeth cofounded giiant pharma after more than 20 years at Merck Frosst. Elizabeth has supported over 100 pre-clinical candidates and several late-stage candidates including: Singulair^®, Vioxx^®, Arcoxia^®, Laropiprant™, Belsomra^® and odanacatib.

Elizabeth retired from Merck after 23 years of service. She established her own company (Kwong Eureka Solutions) as a consultant for small start-up companies and specialty drug products. Kwong Eureka Solutions provides pre-clinical support to lead optimization to Phase III studies for formulation selection, bioavailability enhancement, form selection and preparation for GLP and DRF toxicology studies, including regulatory filing preparation. She recently co-authored and edited a John Wiley technical book entitled “Oral Formulation Roadmap from Early Drug Discovery to Development”. Before she retired, she was Senior Scientific Director at Merck & Co. She is the scientific consultant for the Merck worldwide team for the program support of candidates before nomination. She also leads several initiatives in defining workflow and logistics of lead identification and optimization activities in the drug discovery space.

Elizabeth served on the Board of Directors of the Canadian Society for Pharmaceutical Sciences from 2013 to 2016. She is a member of the College of Pharmacists of British Columbia, and American Association of Pharmaceutical Scientists. She has a myriad of published scientific papers and patents, and is a former Adjunct Professor at Concordia University and the Université de Montréal. She holds a BSc Pharmacy and a PhD in Pharmaceutical Chemistry from the University of British Columbia, and a postdoctoral fellowship from University of Washington in the field of Pharmacokinetics and Drug Metabolism. Elizabeth is a stained-glass creator, loves water colour painting and is an avid park walker.